Ensysce Biosciences (Ensysce Biosciences) Debt-to-Asset : 0.05 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Debt-to-Asset?

Ensysce Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.25 Mil. Ensysce Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Ensysce Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $5.07 Mil. Ensysce Biosciences's debt to asset for the quarter that ended in Mar. 2024 was 0.05.

Ensysce Biosciences Debt-to-Asset Historical Data

The historical data trend for Ensysce Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensysce Biosciences Debt-to-Asset Chart

Ensysce Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

12.13

1.05

0.75

0.32

Ensysce Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial											0.01	0.07	0.11	0.32	0.05

Competitive Comparison of Ensysce Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Ensysce Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensysce Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's Debt-to-Asset falls into.

Ensysce Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Ensysce Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.855	+	0)	/	2.708
	=	0.32

Ensysce Biosciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.246	+	0)	/	5.074
	=	0.05

Ensysce Biosciences (NAS:ENSC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Ensysce Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensysce Biosciences (Ensysce Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037

Website

https://www.ensysce.com

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.

Executives

Bob G Gower	director	402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick	director, officer: Chief Executive Officer	110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman	officer: Chief Medical Officer	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch	director	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano	officer: Chief Development Officer	7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett	officer: Chief Commercial Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt	officer: Chief Medical Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey	officer: Chief Financial Officer	4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang	director, 10 percent owner	C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard	officer: Chief Operating Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright	officer: Chief Business Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin	director	11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037